51³Ô¹ÏÍø

MADRID, SPAIN - MARCH 13: Petia's CEO, Ricardo Troncoso (left), and CSIC researcher, Vicente Larraga (right), during the presentation of an animal vaccine at Iberzoo Propet, the international trade fair for pet professionals, at IFEMA Madrid, on 13 March, 2024 in Madrid, Spain. A team formed by the Spanish National Research Council (CSIC) and Zendal has developed a vaccine against canine leishmaniasis based on recombinant DNA, which reduces the presence of the parasite by more than 90% and improves the clinical signs of the disease. This vaccine is the first in mammals and the second in the world with this technology, based on fragments of genetic information that encode immunogens. It has already been approved by the European Medicines Agency (EMA), which means that it is ready for immediate marketing and distribution. (Photo By Alejandro Martinez Velez/Europa Press via Getty Images)